Accès au site français Welcome to You buy France The french suppliers portal


twitter linkedin facebook viadeo

You buy France


TxCell is developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases. TxCell has developed a proprietary platform, ASTrIA, enabling the development of different Ag-Treg products for many of the severe chronic autoimmune inflammatory diseases. TxCell targets orphan and niche conditions where there are very few treatment options. TxCell's lead product candidate, Ovasave®, has successfully completed a phase I/II clinical trial in Crohn's disease patients, refractory to all current treatments, with promising results. The next step in this program will be an international phase IIb clinical trial to confirm the positive phase I/II study results. This represent a market of around 100 000 patients per year in the seven major pharmaceutical markets. TxCell has signed a strategic partnership with Ferring Pharmaceuticals for the development and commercialisation of Ovasave in Inflammatory Bowel Diseases. Txcell's second product candidate, Col-Treg, is in development for Autoimmune Uveitis, a rare disease of the eye. The next step in this program will be a phase I/II trial.

+ Read more


Company profile

Related activities :

Health, pharmacy, life sciences

Export area :

European Union

Local presence :

European Union

Target countries :

European Union

North America

More information

Social network










Business France contributes to the development and success of French and foreign businesses wishing to expand abroad by supporting them throughout the lifetime of their projects, and is driven by an efficient, result-oriented working culture. > Read more


Discover the French know how:



Rail industry